INCB8761(PF-4136309)CAS# 1341224-83-6 |
Related Products
- INCB3344
Catalog No.:BCC1648
CAS No.:1262238-11-8
- RS 504393
Catalog No.:BCC1910
CAS No.:300816-15-3
- MK-0812
Catalog No.:BCC1755
CAS No.:624733-88-6
- INCB 3284 dimesylate
Catalog No.:BCC1646
CAS No.:887401-93-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1341224-83-6 | SDF | Download SDF |
| PubChem ID | 11192346 | Appearance | Powder |
| Formula | C29H31F3N6O3 | M.Wt | 568.59 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | INCB8761 | ||
| Solubility | DMSO : ≥ 34 mg/mL (59.80 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[2-[(3S)-3-[[4-hydroxy-4-(5-pyrimidin-2-ylpyridin-2-yl)cyclohexyl]amino]pyrrolidin-1-yl]-2-oxoethyl]-3-(trifluoromethyl)benzamide | ||
| SMILES | C1CC(CCC1NC2CCN(C2)C(=O)CNC(=O)C3=CC(=CC=C3)C(F)(F)F)(C4=NC=C(C=C4)C5=NC=CC=N5)O | ||
| Standard InChIKey | ZNSVOHSYDRPBGI-CBQRAPNFSA-N | ||
| Standard InChI | InChI=1S/C29H31F3N6O3/c30-29(31,32)21-4-1-3-19(15-21)27(40)36-17-25(39)38-14-9-23(18-38)37-22-7-10-28(41,11-8-22)24-6-5-20(16-35-24)26-33-12-2-13-34-26/h1-6,12-13,15-16,22-23,37,41H,7-11,14,17-18H2,(H,36,40)/t22?,23-,28?/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | PF-4136309 is a potent, selective, and orally bioavailable CCR2 antagonist, with IC50 of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.In Vitro:PF-4136309 is potent in human chemotaxis activity (IC50=3.9 nM) and in the whole blood assay (IC50=19 nM), with IC50 of 16 and 2.8 nM in mouse and rat chemotaxis assays. PF-4136309 is potent in inhibiting CCR2 mediated signaling events such as intracellular calcium mobilization and ERK (extracellular signal-regulated kinase) phosphorylation with IC50 values of 3.3 and 0.5 nM, respectively. In hERG patch clamp assay, PF-4136309 inhibits hERG potassium current with an IC50 of 20 μM. PF-4136309 is not a cytochrome P450 (CYP) inhibitor, with IC50 values of >30 μM against five major CYP isozymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Moreover, PF-4136309 is not a CYP inducer at concentrations up to 30 μM[1].In Vivo:PF-4136309 (2 mg/kg) exhibits a moderate half-life in both species after iv administration (2.5 and 2.4 h). When administered orally, PF-4136309 (10 mg/kg) is absorbed rapidly, with peak concentration time (Tmax) at 1.2 h for rats and 0.25 h for dogs. A similar half-life is observed in both species between iv dosing and po dosing. PF-4136309 is well absorbed, with an oral bioavailability of 78% in both species[1]. References: | |||||
INCB8761(PF-4136309) Dilution Calculator
INCB8761(PF-4136309) Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7587 mL | 8.7937 mL | 17.5874 mL | 35.1747 mL | 43.9684 mL |
| 5 mM | 0.3517 mL | 1.7587 mL | 3.5175 mL | 7.0349 mL | 8.7937 mL |
| 10 mM | 0.1759 mL | 0.8794 mL | 1.7587 mL | 3.5175 mL | 4.3968 mL |
| 50 mM | 0.0352 mL | 0.1759 mL | 0.3517 mL | 0.7035 mL | 0.8794 mL |
| 100 mM | 0.0176 mL | 0.0879 mL | 0.1759 mL | 0.3517 mL | 0.4397 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
INCB8761(PF-4136309) is a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.
Featured Products
- TP-0903
Catalog No.:BCC6462
CAS No.:1341200-45-0
- Ponasterone A
Catalog No.:BCN6184
CAS No.:13408-56-5
- (S)-4-Carboxyphenylglycine
Catalog No.:BCC6603
CAS No.:134052-73-6
- (R)-4-Carboxyphenylglycine
Catalog No.:BCC6602
CAS No.:134052-68-9
- (RS)-4-Carboxy-3-hydroxyphenylglycine
Catalog No.:BCC6598
CAS No.:134052-66-7
- Selaginellin F
Catalog No.:BCN6420
CAS No.:1340493-24-4
- H-Ala-OtBu.HCl
Catalog No.:BCC3194
CAS No.:13404-22-3
- Methyl beta-D-fructofuranoside
Catalog No.:BCN6183
CAS No.:13403-14-0
- Phaseollin
Catalog No.:BCN4816
CAS No.:13401-40-6
- d-Laserpitin
Catalog No.:BCN3616
CAS No.:134002-17-8
- 4-Hydroxy-3,5-dimethoxybenzaldehyde
Catalog No.:BCN6186
CAS No.:134-96-3
- Lobeline Sulphate
Catalog No.:BCC8203
CAS No.:134-64-5
New Products
- Fmoc-Tyr(PO3Bzl2)-OH
Catalog No.:BCC3566
CAS No.:134150-51-9
- Methylcobalamin
Catalog No.:BCC5188
CAS No.:13422-55-4
- RKI-1447
Catalog No.:BCC1903
CAS No.:1342278-01-6
- Daphnelantoxin B
Catalog No.:BCN3228
CAS No.:134273-12-4
- 3,5-Dibromo-4-[3-(dimethylamino)propoxy]cinnamic acid
Catalog No.:BCN1582
CAS No.:134276-56-5
- BIMU 8
Catalog No.:BCC7928
CAS No.:134296-40-5
- Tolcapone
Catalog No.:BCC2334
CAS No.:134308-13-7
- alpha,beta-Methyleneadenosine 5'-triphosphate trisodium salt
Catalog No.:BCC7603
CAS No.:1343364-54-4
- 2-ThioUTP tetrasodium salt
Catalog No.:BCC7625
CAS No.:1343364-70-4
- Epoxymicheliolide
Catalog No.:BCN8275
CAS No.:1343403-10-0
- Ro 0437626
Catalog No.:BCC7276
CAS No.:134362-79-1
- Epoxomicin
Catalog No.:BCC1235
CAS No.:134381-21-8
Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.[Pubmed:24900280]
ACS Med Chem Lett. 2011 Oct 5;2(12):913-8.
We report the discovery of a new (S)-3-aminopyrrolidine series of CCR2 antagonists. Structure-activity relationship studies on this new series led to the identification of 17 (INCB8761/PF-4136309) that exhibited potent CCR2 antagonistic activity, high selectivity, weak hERG activity, and an excellent in vitro and in vivo ADMET profile. INCB8761/PF-4136309 has entered human clinical trials.
PF-4136309 is a potent, selective, and orally bioavailable CCR2 antagonist, with IC50s of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2.
INCB8761(PF-4136309),1341224-83-6,INCB8761,Natural Products,CCR2, buy INCB8761(PF-4136309) , INCB8761(PF-4136309) supplier , purchase INCB8761(PF-4136309) , INCB8761(PF-4136309) cost , INCB8761(PF-4136309) manufacturer , order INCB8761(PF-4136309) , high purity INCB8761(PF-4136309)
